<DOC>
	<DOCNO>NCT02389972</DOCNO>
	<brief_summary>The primary objective describe effectiveness dasatinib ( Sprycel® ) CML patient China real-world clinical practice setting .</brief_summary>
	<brief_title>Effectiveness Dasatinib Adult Patients With Chronic Myeloid Leukemia China : A Multicenter , Registry Study</brief_title>
	<detailed_description>Breakpoint cluster region ( BCR ) Abelson murine leukemia viral oncogene homolog 1 ( c-ABL ) Chronic myeloid leukemia ( CML )</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Because product registry study , include adult CML patient phase treat dasatinib China meet follow criterion : Willing able provide write informed consent ≥18 year age Confirmed diagnosis CML patient attend physician Naive dasatinib enrollment study treatment receive &lt; 3 month dasatinib treatment Plan receive dasatinib therapy base physician 's clinical judgment Administered dasatinib imatinibresistance intolerance Patients participate clinical trial CML explicitly prohibit recruitment additional study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>